Comparison of seven screening methods in the diagnosis of bladder cancer
Authors:
- Da-Lin HeDHDa-Lin He
- Qiang MaQMQiang Ma
- Xing-Yang WanXWXing-Yang Wan
- Guo-Dong ZhuGZGuo-Dong Zhu
- Lei LiLLLei Li
- Yong LuoYLYong Luo
- Hui HeHHHui He
- Lin YangLYLin Yang
Open Access
- 1 November 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 119 (21) , 1763-1771
Abstract
We compared the validity (evaluated by sensitivity and specificity), reliability (evaluated by reproducibility) and yield (evaluated by predictive value, examining complexity and cost) of individual and combined tests for bladder tumour antigen stat (BTAstat), nuclear matrix protein 22 (NMP22), hyaluronic acid (HA), survivin, CD44v6, vascular endothelial growth factor (VEGF), and voided urine cytology (VUC) in detecting bladder cancer. And at the same time we evaluated the clinical value of these seven detecting methods in the diagnosis of bladder cancer. The six markers and VUC were detected in the urine of cancer group (151 patients with bladder cancer) and two control groups (50 patients with benign urological diseases and 50 healthy controls). The sensitivity, specificity, predictive value, reproducibility, examining complexity and checking cost of each marker and combined markers were calculated. There was a significant difference between bladder cancer group and the two control groups. The sensitivity, specificity and positive predictive value were as follows: VUC (36.4%, 100.0%, 100%), BTAstat (76.8%, 87.0%, 89.9%), NMP22 (77.5%, 81.0%, 86.0%), HA (82.8%, 83.0%, 88.0%), survivin (70.2%, 85.0%, 87.6%), CD44v6 (50.3%, 79.0%, 78.4%), and VEGF (68.2%, 93.0%, 93.6%). The highest sensitivities were 91.4% for NMP22+BTAstat and HA+NMP22, whereas the combined marker with the lowest sensitivity (62.3%) was VUC+CD44v6. The highest specificity was 93.0% for the combined use of VUC+VEGF and HA+CD44v6 had the lowest specificity (73.0%). The most convenient examining method was the detection for BTAstat, the lowest cost was the detection for HA, and the best reproducibility were the detection for BTAstat and VUC. All the markers have obvious clinical value in diagnosis of bladder cancer. The use of BTAstat+HA or NMP22+BTAstat are better examining methods in terms of validity, reliability, and yield. Chin Med J2006;119(21):1763–1771Keywords
This publication has 22 references indexed in Scilit:
- Detection of Bladder Cancer Using a Point-of-Care Proteomic AssayJAMA, 2005
- A SIDE BY SIDE COMPARISON OF CYTOLOGY AND BIOMARKERS FOR BLADDER CANCER DETECTIONJournal of Urology, 2004
- Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladderUrological Research, 2003
- Improved Detection of Urothelial Carcinomas with Fluorescence Immunocytochemistry (uCyt+ Assay) and Urinary Cytology: Results of a French Prospective Multicenter StudyLaboratory Investigation, 2003
- Immunocyt Test Improves the Diagnostic Accuracy of Urinary Cytology: Results of a French Multicenter StudyJournal of Urology, 2003
- Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid–hyaluronidase and BTA‐Stat testsCancer, 2002
- Usefulness of the BTA stat Test for the diagnosis of bladder cancerUrology, 2001
- URINE CYTOLOGYUrologic Clinics of North America, 2000
- Bladder cancer: state-of-the-art careCA: A Cancer Journal for Clinicians, 1998
- Statistics Notes: Diagnostic tests 3: receiver operating characteristic plotsBMJ, 1994